Mylan gets DCGI nod for anti-TB drug pretomanid
Mylan on Wednesday said the Drugs Controller General of India (DCGI) has approved its anti-tuberculosis drug pretomanid for conditional access under the National Tuberculosis Elimination Programme. Pretomanid has been developed by non-profit organisation TB Alliance and is part of a 3-drug, 6-month, all-oral regimen for treatment of pulmonary extensively drug-resistant TB and non-responsive multi drug-resistant TB. Initially, Mylan will make the drug available via a donation of 400 courses to the NTEP.
